BioSpace News Archive

Ionis Pharmaceuticals, Inc. announced that topline results from the Phase 2b SOLANO study in patients with hypercholesterolemia demonstrated that 60mg of ION449 administered monthly achieved a statistically significant 62.3% reduction in low-density lipoprotein cholesterol levels after 28 weeks compared to placebo, meeting the study’s primary efficacy endpoint.

Hummingbird Bioscience, a data-driven precision biotherapeutics company discovering and developing transformative biologic medicines for hard-to-treat diseases, announced the official opening of its office and research facilities at the Singapore Science Park.

Janux Therapeutics, Inc., a biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager and Tumor Activated Immunomodulator platforms, announced the appointment of Brenda Van Vreeswyk as Head of Human Resources.

AlivaMab Discovery Services, a leader in the discovery of superior antibody-based therapeutics, announced that Larry Green has reassumed the role of Chief Executive Officer, effective immediately.

After seven years of development work, Precisis GmbH, headquartered in Heidelberg, has received the CE certification for its minimally invasive brain pacemaker EASEE.

Caris Life Sciences® announced a partnership with Flatiron Health, a healthtech company dedicated to helping cancer centers thrive and deliver better care for patients, to integrate Caris’ market leading molecular testing portfolio with OncoEMR®, a leading cloud-based electronic medical record tool.

Arch Therapeutics, Inc. today confirmed the first shipments of AC5 ® Advanced Wound System (“AC5”) under the Company’s new reimbursement support program (the “Program”).

NovaBay ® Pharmaceuticals, Inc. announces that management will present at the Ladenburg Thalmann 2022 Healthcare Conference on Thursday, September 29 at 9:00 a.m. Eastern time (6:00 a.m. Pacific time).

CLS Americas today announced the companies will exhibit and demonstrate their respective TRANBERG™ Thermal Therapy System for focal laser ablation and Focalyx® Fusion medical device at the FOCAL 2022 Conference being held September 22-24, 2022 in Los Angeles.

CASI Pharmaceuticals, Inc. today announced that CASI Biopharmaceuticals (Wuxi) Co., Ltd, a subsidiary of CASI Pharmaceuticals, Inc. (“CASI Wuxi”), entered into an Equity Transfer Agreement with Shenzhen Jiadao Gongcheng Equity Investment Fund, LLP (“Jiadao Gongcheng”), pursuant to which CASI Wuxi agreed to transfer its equity interest in Juventas Biotechnology (Tianjin) Co., Ltd.